News about Quality / GMP

Agilent Secures EU Certification for Companion Diagnostic to Guide Keytruda Therapy in Ovarian Cancer

Agilent Secures EU Certification for Companion Diagnostic to Guide Keytruda Therapy in Ovarian Cancer

PD-L1 IHC 22C3 pharmDx gains CE-marked indication to identify eligible patients with epithelial ovarian, fallopian tube and primary peritoneal carcinoma for pembrolizumab treatment.

Quality / GMP | 27/07/2026 | By News Bureau

EU Approves AstraZeneca's Etcamah Combination for ESR1-Mutated Advanced Breast Cancer

EU Approves AstraZeneca's Etcamah Combination for ESR1-Mutated Advanced Breast Cancer

The European Commission has approved AstraZeneca’s Etcamah in combination with CDK4/6 inhibitors for ESR1-mutated ER-positive, HER2-negative advanced breast cancer, following Phase 3 data demonstrating a 56% reduction in the risk of disease progression or death.

Quality / GMP | 24/07/2026 | By News Bureau

FDA Grants Priority Review to Pfizer's Talzenna-Xtandi Combination Advanced Prostate Cancer

FDA Grants Priority Review to Pfizer's Talzenna-Xtandi Combination Advanced Prostate Cancer

Pfizer’s Talzenna-Xtandi combination receives FDA Priority Review for HRR gene-altered metastatic castration-sensitive prostate cancer, with Phase 3 data demonstrating a 52 percent reduction in the risk of disease progression or death.

Quality / GMP | 24/07/2026 | By News Bureau

Chiesi Secures UK Approval for World's First Low-Carbon pMDIs Using Next-Generation Propellant

Chiesi Secures UK Approval for World's First Low-Carbon pMDIs Using Next-Generation Propellant

MHRA authorises Clenil Modulite inhalers with a non-PFAS, low global warming potential propellant, reducing carbon emissions by up to 90 percent while maintaining therapeutic efficacy.

Quality / GMP | 23/07/2026 | By News Bureau

JCR Pharmaceuticals' Izcargo Receives First International Approval in UAE for Hunter Syndrome Treatment

JCR Pharmaceuticals' Izcargo Receives First International Approval in UAE for Hunter Syndrome Treatment

JCR Pharmaceuticals secures its first international approval for Izcargo in the UAE, expanding access to its innovative blood-brain barrier-penetrating therapy for patients with Hunter syndrome and advancing rare disease treatment across the MENA region.

Quality / GMP | 23/07/2026 | By News Bureau

Dyne Therapeutics' Duchenne Muscular Dystrophy Therapy Receives FDA Priority Review

Dyne Therapeutics' Duchenne Muscular Dystrophy Therapy Receives FDA Priority Review

FDA accepts Biologics License Application for investigational exon 51-skipping therapy z-rostudirsen, with a regulatory decision expected by January 2027.

Quality / GMP | 22/07/2026 | By News Bureau

CuraTeQ Biologics Secures ANVISA Approval for Hyderabad Biosimilars Manufacturing Facility

CuraTeQ Biologics Secures ANVISA Approval for Hyderabad Biosimilars Manufacturing Facility

CuraTeQ Biologics has received ANVISA GMP approval for its Hyderabad biosimilars manufacturing facility, strengthening its global regulatory credentials and enabling expanded supply of biosimilar products to Brazil and the wider Latin American market.

Quality / GMP | 22/07/2026 | By News Bureau 155

Can-Fite BioPharma Secures Australian Patent for Namodenoson in Advanced Metastatic Cancer

Can-Fite BioPharma Secures Australian Patent for Namodenoson in Advanced Metastatic Cancer

Can-Fite BioPharma has secured an Australian patent covering the use of Namodenoson for advanced metastatic cancer, strengthening intellectual property protection as the drug advances through late-stage clinical development for liver and pancreatic cancers.

Quality / GMP | 15/07/2026 | By News Bureau

TolerogenixX Secures EU Orphan Drug Designation for MIC-Lx in Living-Donor Kidney Transplantation

TolerogenixX Secures EU Orphan Drug Designation for MIC-Lx in Living-Donor Kidney Transplantation

European Commission grants orphan status to Tolerogenix’s personalized cell therapy following EMA recommendation, strengthening its regulatory pathway alongside recent PRIME designation.

Quality / GMP | 14/07/2026 | By News Bureau

China Grants Priority Review to Leads Biolabs' Opamtistomig for Advanced Neuroendocrine Carcinoma

China Grants Priority Review to Leads Biolabs' Opamtistomig for Advanced Neuroendocrine Carcinoma

NMPA accepts biologics license application under expedited review pathway for investigational PD-L1/4-1BB bispecific antibody targeting advanced extrapulmonary neuroendocrine carcinoma after multiple prior therapies.

Quality / GMP | 13/07/2026 | By News Bureau 108

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members